News

The selection of articles I chose for this week is an attempt to capture recent events, along with one older article, showcasing the range of articles relating to the science and increased awareness being brought to the CF community ‘Salty Girls’ photo Series Challenges Notions of Beauty and Cystic Fibrosis…

Celtaxsys has announced that the company’s phase 2 clinical trial to evaluate CTX-4430, its investigational treatment for cystic fibrosis (CF), will be supported by a $5 million grant from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis…

Corbus Pharmaceuticals Holdings, Inc., a company focused on the development and commercialization of new therapies for rare, chronic, serious inflammatory and fibrotic diseases, recently announced that its President and Chief Scientific Officer Dr. Mark A. Tepper is presenting a poster (June 1-2) at the 2015 Cystic Fibrosis Foundation Research…

The Best Late Stage Product Development Company Award was recently granted to Parion Sciences by the Triangle Business Journal and accounting firm BDO. The company, which is focused on creating novel therapies for both pulmonary and ocular medical conditions, was presented with the award at an event in Cary, North Carolina, and is part of the third-annual…

Dr. Ewa Goldys and research colleagues at the Centre for Nanoscale BioPhotonics (CNBP) at Macquarie University in Sydney have published a research paper in the open access journal Sensors, claiming that diseases such as cystic fibrosis, acute pancreatitis and rheumatoid arthritis can be diagnosed…

Denmark-based Serendex Pharmaceuticals, a company developing drugs to treat severe respiratory conditions, recently announced the initiation of a Phase I clinical trial for their drug candidate Molgradex, based on their Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). The compound uses Novozymes‘ recombinant human albumin named Recombumin as an effective, versatile stabilizer that eases…

Despite suffering from cystic fibrosis (CF), having spent most of her time during high school either at home or hospitalized and having undergone a double-lung transplant, Rachel Sweet will graduate high school on June 2nd, becoming yet another example of the determination seen in those who live with the disease.

In a recent agreement with the Indiana University Research and Technology Corp. (IURTC), La Jolla Pharmaceutical Co. acquired intellectual property rights covering next-generation derivatives of gentamicin, an antibiotic used in the treatment of several types of bacterial infections, namely heart, urinary tract, and pregnancy-related infections. Gentamicin treatment is effective…

What We Hope For I have found myself chasing a deferred hope waiting for my health to change, while watching it steadily decline. The release of Kayldeco by Vertex Pharmaceuticals Inc. in 2012 was a demonstration that the next generation of medications in cystic fibrosis therapy could begin to…

Despite every effort to design a drug effective in helping cystic fibrosis patients with defective CFTR proteins, sometimes drugs are thwarted by mechanisms orchestrated by other proteins within cells. A group of researchers from the Department of Human Genetics at National Health Institute Doutor Ricardo Jorge in Portugal recently published…